MetaCap

Eton Pharmaceuticals (ETON) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eton Pharmaceuticals (ETON) has outperformed Vera Therapeutics (VERA) over the past year, gaining 269.7% versus a loss of 10.6%. Over five years, ETON leads with a +1341.9% price change compared with -15.2% for VERA. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.76 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ETON+269.68%VERA-10.58%
+332%+151%-29%
Nov 21, 20251 yearNov 20, 2026
ETON+1234.43%VERA-18.43%
+1371%+610%-152%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ETON versus VERA key metrics
MetricETONVERA
Share price$60.85$25.45
Market cap$1.76B$1.84B
1-day change-0.83%-4.86%
YTD return+259.85%-49.74%
1-year return+269.68%-10.58%
5-year return+1341.94%-15.17%
P/E ratio (TTM)39.51—
Forward P/E18.41—
EPS (TTM)$1.54$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$79.95M—
Revenue growth (YoY)+104.94%—
Net income (latest FY)$-4.60M$-299.62M
Gross margin53.46%—
Operating margin-1.06%—
Net margin-5.75%—
52-week high$70.64$56.05
52-week low$14.27$25.08
Distance from 52-week high-13.86%-54.59%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+32.70%+180.39%
Average volume570.79K1.95M
Shares outstanding28.84M72.30M
Employees44362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ETON has outperformed VERA by 280.3 percentage points over the past year.

About Eton Pharmaceuticals

ETON stock →

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

ETON vs VERA FAQ

Which is bigger, Eton Pharmaceuticals or Vera Therapeutics?

Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.76B for Eton Pharmaceuticals (ETON).

Which stock has performed better over the past year, ETON or VERA?

ETON returned +269.68% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Eton Pharmaceuticals and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons